Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-14
DOI
10.1186/s12967-020-02262-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions
- (2019) Jing Zhu et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Cancer stem cells: A brief review of current status
- (2018) Alican Kuşoğlu et al. GENE
- Cancer stem cells (CSCs) in cancer progression and therapy
- (2018) Masoud Najafi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- New Systemic Treatments in Advanced Hepatocellular Carcinoma
- (2018) Marco Sanduzzi-Zamparelli et al. LIVER TRANSPLANTATION
- Wnt–β-catenin signalling in liver development, health and disease
- (2018) Maria J. Perugorria et al. Nature Reviews Gastroenterology & Hepatology
- Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
- (2017) Masaru Katoh INTERNATIONAL JOURNAL OF ONCOLOGY
- The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
- (2016) T. Tellez et al. CURRENT MEDICINAL CHEMISTRY
- Clusterin as a therapeutic target
- (2016) Mark R. Wilson et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Silencing clusterin gene transcription on effects of multidrug resistance reversing of human hepatoma HepG2/ADM cells
- (2015) Wenjie Zheng et al. TUMOR BIOLOGY
- Hepatocellular carcinoma: clinical frontiers and perspectives
- (2014) Jordi Bruix et al. GUT
- Wnt/β-catenin signalling: from plasma membrane to nucleus
- (2013) Wantae Kim et al. BIOCHEMICAL JOURNAL
- The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells
- (2013) K. Wu et al. CLINICAL CANCER RESEARCH
- Exon-Skipping Strategy by Ratio Modulation between Cytoprotective versus Pro-Apoptotic Clusterin Forms Increased Sensitivity of LNCaP to Cell Death
- (2013) Abdellatif Essabbani et al. PLoS One
- Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma
- (2012) Peng Xiu et al. CANCER SCIENCE
- PI3K/Akt-dependent phosphorylation of GSK3β and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration
- (2012) Jiaojing Liu et al. CELLULAR SIGNALLING
- Clinical significance of serum clusterin as a biomarker for evaluating diagnosis and metastasis potential of viral‐related hepatocellular carcinoma
- (2012) Abeer M. Nafee et al. CLINICAL BIOCHEMISTRY
- Clusterin is a specific stabilizer and liberator of extracellular cathepsin K
- (2012) Marko Novinec et al. FEBS LETTERS
- Advances and Challenges in Basic and Translational Research on Clusterin
- (2009) I. P. Trougakos et al. CANCER RESEARCH
- Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis
- (2009) Yi Wang et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Helicobacter pyloriVacA-induced Inhibition of GSK3 through the PI3K/Akt Signaling Pathway
- (2008) Masaaki Nakayama et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search